immunoglobulin
ig
also
call
antibodi
present
milk
colostrum
lactat
speci
ig
divid
class
differ
physicochem
structur
biolog
activ
major
ig
class
bovin
human
milk
iga
igg
igm
bovin
colostr
ig
provid
newborn
calf
passiv
immun
protect
microbi
infect
calf
immun
system
matur
colostr
ig
prepar
design
farm
anim
commerci
avail
mani
year
potenti
health
benefi
ts
attribut
bovin
colostrum
increas
manufactur
market
colostr
igbas
dietari
supplement
also
human
use
furthermor
specifi
c
antimicrobi
antibodi
produc
colostrum
immun
cow
vaccin
made
pathogen
microorgan
antibodi
concentr
use
formul
socal
immun
milk
prepar
prepar
proven
effect
prevent
anim
human
infect
caus
eg
rotaviru
shigella
fl
exneri
escherichia
coli
clostridium
diffi
cile
streptococcu
mutan
cryptosporidium
parvum
helicobact
pylori
therapeut
effi
caci
howev
seem
limit
immun
milk
product
commerci
expect
futur
use
eg
support
mean
antibiot
treatment
prevent
hospit
infect
recogn
year
matern
colostrum
milk
offer
passiv
protect
newborn
infant
enter
pathogen
primarili
via
transfer
immunoglobulin
ig
associ
bioactiv
factor
ehrlich
rumin
neonat
born
virtual
without
ig
therefor
colostr
ig
essenti
surviv
probabl
due
uniqu
function
ig
repres
major
protein
fraction
colostrum
account
total
protein
content
butler
marnila
korhonen
ig
fraction
concentr
colostrum
chees
whey
market
commerci
feed
supplement
replac
colostrum
mainli
neonat
calv
pig
prevent
gastrointestin
infect
scammel
mehra
et
al
advent
function
food
increas
interest
bioactiv
compon
bovin
colostrum
milk
potenti
ingredi
healthpromot
foodstuff
even
biopharmaceut
end
scientifi
c
commerci
attent
focus
develop
bovinederiv
ig
product
contain
specifi
c
antibodi
target
prevent
treatment
microbi
infect
human
korhonen
et
al
prepar
describ
immun
milk
concept
date
back
petersen
campbel
fi
rst
suggest
oral
administ
bovin
colostrum
hyperimmun
cow
could
provid
passiv
immun
protect
human
campbel
petersen
sinc
larg
number
anim
human
studi
carri
demonstr
prepar
effect
prevent
treatment
human
anim
diseas
caus
variou
pathogen
microb
review
see
weiner
et
al
korhonen
et
al
liliu
marnila
hoerr
bostwick
korhonen
marnila
mehra
et
al
articl
review
current
state
knowledg
properti
bovin
ig
util
ingredi
immun
milk
prepar
applic
prepar
prevent
treatment
variou
microbi
infect
human
ig
carri
biolog
function
antibodi
present
colostrum
milk
lactat
speci
mammal
fi
known
class
ig
character
igg
igm
iga
igd
ige
major
ig
class
bovin
human
milk
iga
igg
igm
basic
chemic
structur
ig
similar
biolog
function
differ
although
principl
contribut
major
defenc
mechan
foreign
materi
recogn
bodi
immun
system
ig
account
total
protein
content
colostrum
wherea
milk
account
total
protein
predomin
ig
class
bovin
lacteal
secret
compar
iga
human
milk
elfstrand
et
al
marnila
korhonen
tabl
provid
concentr
differ
ig
class
bovin
colostrum
milk
ig
molecul
class
symmetr
multichain
glycoprotein
compos
two
ident
glycosyl
heavi
chain
two
ident
nonglycosyl
light
chain
basic
structur
monomer
ig
similar
see
fig
igg
class
consid
gener
model
monomer
ig
molecular
weight
light
chain
around
kda
heavi
chain
kda
molecular
weight
complet
ig
molecul
vari
around
kda
light
heavi
chain
contain
domain
refer
constant
region
c
l
c
h
variabl
region
v
l
v
h
light
chain
attach
heavi
chain
disulphid
bond
also
two
heavi
chain
held
togeth
two
disulphid
bond
near
hing
region
give
molecul
structur
fl
exibl
need
antibodyantigen
interact
nezlin
two
ident
antigenbind
site
need
interact
form
ntermin
region
one
heavi
chain
variabl
region
one
light
chain
v
l
region
determin
immunolog
specifi
citi
antigen
bind
occur
interact
antigen
region
ig
class
subclass
determin
gene
encod
constant
region
heavi
chain
butler
bovin
igg
molecul
occur
dominantli
two
subclass
igg
igg
monomer
igm
iga
similar
basic
structur
igg
except
differ
heavi
chain
structur
addit
ctermin
octapeptid
heavi
chain
iga
butler
nezlin
monomer
iga
occur
serum
milk
present
dimer
compris
two
iga
molecul
join
togeth
polypeptid
jchain
addit
kd
secretori
compon
secretori
iga
siga
molecular
weight
kda
resist
proteolysi
therefor
stabl
gastrointestin
tract
antibodi
without
secretori
compon
igm
circular
pentam
consist
fi
subunit
similar
monomer
iga
igg
link
togeth
circular
mode
disulphid
bond
j
chain
molecular
weight
igm
approxim
kda
see
fig
physicochem
properti
ig
present
tabl
proteolysi
ig
papain
cleav
near
hing
region
two
antigen
bindingsit
fabfrag
form
ntermin
part
one
heavi
one
light
chain
third
ctermin
fragment
term
fcpart
differ
ig
class
impact
upon
cleavag
pattern
enzymat
proteolysi
instanc
cleavag
bovin
pepsin
result
two
fab
one
fc
part
wherea
fab
part
remain
togeth
one
disulphur
bridg
result
one
f
one
fc
fragment
cleav
pepsin
heyermann
butler
ig
produc
b
lymphocyt
plasma
cell
diversifi
ed
b
cell
solubl
ig
function
fl
exibl
adaptor
cellular
humor
immun
bind
antigen
exhibit
one
effector
function
fab
part
attach
antigen
part
mostli
fc
region
interact
element
immun
system
mani
pathogen
organ
attach
epitheli
line
obligatori
fi
rst
step
establish
colon
infect
mani
pathogen
receptor
eg
fi
mbriae
epitheli
surfac
thu
prevent
microbi
adhes
epitheli
line
import
mechan
siga
antibodi
protect
host
woof
kerr
colostrum
human
milk
protect
neonat
intestin
mucosa
epec
infect
inhibit
bacteri
adhes
epitheli
cell
carbonar
et
al
effect
shown
mediat
colostrum
milk
siga
et
al
carbonar
et
al
carbonar
et
al
fernand
et
al
et
al
oligosaccharid
present
human
milk
cravioto
et
al
mcell
intestin
epithelia
specifi
c
receptor
siga
antigensigareceptor
complex
transcytos
mcell
lymphoid
tissu
antigen
present
induct
mucos
immun
respons
woof
kerr
abil
ig
form
crosslink
surfac
antigen
result
network
cell
remov
mechan
bodi
agglutin
microb
reduc
capabl
adher
surfac
agglutin
microb
usual
abl
releas
toxin
colon
host
normal
colostrum
milk
known
contain
natur
antibodi
agglutin
larg
number
pathogen
nonpathogen
microorgan
bostwick
et
al
korhonen
et
al
ig
bind
bacteri
toxin
thereaft
recogn
effect
phagocyt
leukocyt
mani
bacteri
toxin
must
fi
rst
activ
transport
via
receptor
insid
host
cell
caus
cell
death
block
toxin
may
prevent
intern
host
cell
also
ig
inhibit
reduc
product
toxin
harm
compon
inhibit
bacteri
metabol
block
enzym
receptor
block
may
also
reduc
abil
pathogen
produc
structur
need
adher
epithelia
specifi
c
ig
protect
viral
infect
bind
virus
prevent
viru
replic
block
receptor
mediat
internalis
virus
host
cell
specifi
c
ig
augment
recognit
phagocytosi
antigen
leukocyt
opsonis
dival
polyval
bind
ig
antigen
structur
result
conform
chang
ig
molecul
process
enabl
fc
portion
bind
correspond
fc
receptor
leukocyt
surfac
receptor
bind
lead
variou
immun
cell
effector
function
depend
cell
ig
leukocyt
type
leukocyt
integr
part
normal
milk
colostrum
vital
import
defend
mammari
gland
pathogen
korhonen
et
al
specifi
c
ig
rare
cidal
microorgan
may
disturb
cellular
metabol
block
receptor
enzym
caus
structur
alter
lead
immobil
increas
membran
permeabl
impair
cell
growth
ig
may
contribut
kill
microb
activ
classic
pathway
complement
blood
tissu
activ
complement
mediat
bacteriolyt
reaction
may
import
function
ig
signifi
canc
mechan
milk
remain
obscur
bovin
human
colostrum
contain
activ
complement
system
particip
immun
defens
udder
butler
igm
antibodi
although
produc
smaller
amount
igg
consider
effi
cient
igg
regard
activ
includ
complement
fi
xation
opson
agglutin
bacteria
bovin
igg
b
effect
igg
activ
classic
pathway
complement
bastidacorquera
specifi
c
igm
prevent
effect
migrat
bacteria
bind
fl
agella
use
movement
bovin
iga
fi
x
complement
opson
bacteria
agglutin
antigen
neutral
virus
bacteri
toxin
siga
dimer
found
mucos
secret
main
function
protect
mucos
barrier
bind
microb
prevent
attach
epithelium
contribut
antigen
present
milk
ig
also
found
exert
synergist
effect
activ
nonspecifi
c
antimicrobi
factor
milk
lactoferrin
lysozym
well
lactoperoxidasethiocyanatehydrogen
peroxid
system
loimaranta
et
al
bostwick
et
al
tradit
globulin
fraction
isol
colostr
whey
precipit
either
ammonium
sulphat
ethanol
chemic
method
howev
econom
suitabl
larg
scaleproduct
ig
although
yield
rather
pure
ig
fraction
challeng
isol
activ
ig
colostrum
complex
composit
sensit
ig
heat
treatment
rapid
develop
new
chromatograph
membranesepar
technolog
last
thirti
year
possibl
isol
individu
milk
protein
largescal
base
techniqu
great
number
pilotor
industrialscal
method
develop
patent
fraction
isol
ig
colostr
chees
whey
review
see
korhonen
korhonen
pihlanto
method
recoveri
rate
ig
vari
level
present
start
materi
elfstrand
et
al
specifi
c
chromatograph
techniqu
immobil
metal
chelat
chromatographi
immunoaffi
niti
chromatographi
cationexchang
chromatographi
appli
improv
yield
puriti
immunoglobulin
prepar
fukumoto
et
al
akita
lichan
microfi
ltration
mf
combin
ultrafi
ltration
uf
bovin
equin
caprin
colostrum
led
iggtot
solid
puriti
piot
et
al
use
chees
whey
membran
concept
select
membran
separ
ph
manipul
mehra
kelli
produc
igrich
prepar
protein
composit
similar
produc
colostr
whey
korhonen
et
al
use
variou
mf
method
uf
mf
revers
osmosi
cationexchang
resin
molecular
siev
concentr
ig
colostr
whey
ig
level
fi
nal
freezedri
concentr
vari
expand
bed
adsorpt
chromatographi
ebac
new
technolog
appli
isol
ig
chees
whey
use
adsorb
tailor
ligand
chemistri
nielsen
et
al
ebac
provid
signifi
cant
advantag
convent
pack
bed
column
chromatographi
igpur
achiev
upscal
method
technolog
properti
ig
studi
extens
protein
known
affect
mani
dairi
process
see
review
mehra
et
al
ig
may
inhibit
retard
activ
rennet
enzym
bacteri
origin
normal
milk
notic
due
rel
low
ig
concentr
case
mastit
milk
ig
concentr
milk
increas
eg
ad
colostrum
rennet
may
retard
antimicrobi
properti
ig
may
advers
impact
upon
ferment
process
retard
ferment
dairi
starter
note
colostrum
mastit
milk
contain
increas
amount
ig
also
high
ig
concentr
may
advers
affect
antibiot
residu
test
base
microbi
growth
caus
fals
posit
result
korhonen
ig
contribut
cream
format
agglutin
fat
globul
process
acceler
ascent
cream
surfac
phenomenon
attribut
primarili
igm
term
cryoglobulin
cold
agglutinin
agglutin
properti
ig
howev
inactiv
heat
treatment
pasteur
mechan
agit
among
dairi
process
properti
ig
affect
thermal
treatment
high
temperatureshort
time
htst
pasteur
sec
ig
activ
lost
wherea
ultra
high
temperatur
uht
treatment
sec
evapor
process
destroy
specifi
c
immun
activ
milk
due
ig
denatur
lichan
et
al
contrast
studi
mainer
et
al
mainer
et
al
report
bovin
milk
ig
could
resist
htst
pasteur
treatment
without
affect
structur
igg
iga
igm
concentr
denatur
laboratori
experi
also
htst
pasteur
littl
effect
activ
bovin
colostr
igg
origin
rotaviru
neutral
activ
reduc
recent
studi
mcmartin
et
al
demonstr
rapid
heat
inactiv
igg
start
temperatur
higher
much
viru
neutral
activ
ig
lost
less
two
minut
hand
heat
moder
high
qualiti
colostrum
least
min
effect
mean
igg
concentr
titer
neutral
antibodi
bovin
viral
diarrhea
viru
type
storag
stabil
studi
observ
bovin
igg
ad
uhttreat
milk
retain
specifi
c
immun
activ
sever
month
fukumoto
et
al
also
ig
molecul
seem
retain
specifi
c
activ
well
milk
powder
irrespect
storag
temperatur
mehra
et
al
bacteri
ferment
milk
yoghurt
probiot
bacteria
found
reduc
signifi
cantli
activ
colostr
antibodi
ad
milk
storag
period
day
wei
et
al
progress
understand
mechan
ig
mediat
immun
function
rapid
develop
industri
fraction
technolog
rais
interest
develop
formul
supplement
bovin
colostr
chees
whey
deriv
ig
current
commerci
ig
product
prepar
colostrum
nonimmun
cow
remov
fat
follow
microfi
ltration
pasteur
condit
retain
biolog
activ
ig
product
usual
form
spraydri
freezedri
powder
form
fi
ltere
colostr
whey
liquid
concentr
dri
product
includ
whole
colostrum
powder
skim
powder
skim
colostrum
protein
concentr
colostrum
whey
concentr
prepar
test
clinic
certain
physiolog
function
prevent
treatment
microbi
infect
accordingli
product
boast
specifi
c
health
nutrit
function
claim
boost
immun
microbi
infect
speed
recoveri
physic
endur
exercis
scammel
kelli
tripathi
vashishtha
howev
case
clinic
evid
relat
product
limit
avail
specifi
citi
natur
antibodi
found
milk
colostrum
differ
cow
refl
ect
wide
spectrum
antigen
anim
encount
past
environ
ingest
feedstuff
korhonen
et
al
kelli
antibodi
titr
certain
antigen
pathogen
structur
eg
virul
factor
rais
sever
hundr
time
immun
cow
parturit
vaccin
contain
antigen
korhonen
et
al
result
immun
colostra
product
made
thereof
fundament
differ
antimicrobi
properti
effi
caci
pathogen
normal
colostrum
two
concept
therefor
differenti
emphas
fact
normal
colostrum
prepar
made
countri
regard
food
dietari
supplement
wherea
ig
contain
prepar
immun
cow
often
regard
pharmaceut
eg
eu
usa
regulatori
statu
defi
ned
scammel
hoerr
bostwick
mehra
et
al
tabl
list
commerci
ig
immun
milk
prepar
develop
last
decad
well
known
low
ph
gastric
acid
reduc
signifi
cantli
activ
ingest
ig
furthermor
ingest
ig
subject
degrad
intestin
proteas
stomach
enzymat
hydrolysi
pepsin
fragment
igg
molecul
f
fabc
pfc
fv
fragment
nezlin
small
intestin
trypsin
chymotrypsin
carboxypeptidas
elastas
initi
degrad
antibodi
f
fab
fc
fragment
secretori
piec
milk
siga
protect
ig
form
digest
proteolyt
enzym
siga
present
human
colostrum
pass
undegrad
gut
human
infant
also
bovin
igg
make
except
sinc
rather
resist
trypsin
bovin
colostrum
mastit
milk
contain
compound
inhibit
trypsin
activ
result
f
fab
fragment
retain
least
part
neutral
adhes
inhibit
activ
intestin
pacyna
et
al
supplement
whole
milk
immun
colostrum
contain
specifi
c
ig
rotaviru
ml
supplement
whole
milk
administ
children
three
time
day
six
day
antirotaviru
ig
activ
detect
elisa
method
fecal
specimen
obtain
studi
kelli
et
al
demonstr
oral
administ
bovin
anticlostridium
diffi
cile
ig
concentr
could
recov
stool
human
infant
adult
form
f
fab
fragment
surviv
igg
increas
remark
encapsul
gelatin
concept
immun
milk
ie
transfer
passiv
immun
milk
ig
date
back
sinc
great
number
clinic
studi
publish
effi
caci
variou
immun
nonimmun
milk
ig
prepar
prevent
treatment
variou
gastrointestin
microbi
diseas
recent
studi
review
mehra
et
al
korhonen
marnila
weiner
thu
protocol
result
numer
studi
discuss
detail
articl
briefl
gener
tendenc
studi
oral
administ
bovin
milk
colostr
ig
case
prove
effect
prevent
oral
mediat
infect
colostr
milk
ig
effect
agglutin
bacteria
xu
et
al
bovin
colostrum
colostr
prepar
prevent
effect
attach
pathogen
cell
epitheli
line
howev
sinc
bovin
colostrum
contain
one
adhes
inhibit
factor
import
specifi
c
ig
often
known
palmeira
et
al
observ
inhibit
enteropathogen
e
coli
adher
cultur
cell
bovin
colostrum
caus
igg
fraction
mediat
high
molecular
weight
fraction
howev
studi
inhibit
pathogen
adhes
epitheli
cell
attribut
presenc
specifi
c
ig
casswal
et
al
show
specifi
c
bovin
immun
colostr
prepar
block
almost
helicobact
pylori
attach
human
gastric
mucos
tissu
vitro
bind
lewi
b
glycoconjug
control
colostr
prepar
nonimmun
cow
ineffi
cient
doyl
et
al
report
hyperimmun
bovin
colostr
ig
inhibit
cryptosporidium
parvum
adher
epitheli
mdck
cell
infect
vitro
assay
inhibit
correl
protect
capac
bovin
colostrum
vivo
signifi
cant
adhes
inhibit
observ
control
prepar
colostra
sham
immun
cow
bojsen
et
al
studi
effi
caci
bovin
macromolecular
whey
protein
fraction
prevent
infect
two
human
intestin
cell
line
fh
int
four
differ
rotaviru
strain
wa
rrv
ym
rf
major
compon
protein
fraction
inhibit
effect
rotaviru
infect
vitro
shown
bovin
igg
fraction
one
affect
rotaviru
shed
vivo
mous
model
treatment
alreadi
establish
infect
promis
therapeut
effect
report
mainli
diseas
infect
maintain
reattach
reinfect
eg
insid
oral
caviti
gastrointestin
lumen
secret
toxin
infl
ammatori
compound
involv
neutral
specifi
c
colostr
ig
diseas
caus
enterotoxigen
escherichia
coli
strain
cryptosporidium
parvum
candida
spp
shigella
fl
exneri
rotaviru
exampl
instanc
clinic
studi
closer
look
taken
hereund
recent
progress
develop
bovin
immun
milk
target
streptoccu
mutan
clostridium
diffi
cile
tabl
provid
data
recent
clinic
studi
carri
colostr
ig
immun
milk
prepar
pathogenesi
dental
cari
caus
streptococcu
mutan
involv
seri
attach
bind
event
lead
accumul
cariogen
bacteria
suffi
cient
caus
cari
immun
strategi
streptococc
adhesin
glucosyltransferas
enzym
gtf
shown
effect
interfer
pathogenesi
mutan
streptococci
smith
et
al
block
activ
mutan
glucan
bind
protein
serv
anoth
effect
strategi
sinc
human
immun
activ
cari
bacteria
due
risk
side
effect
bovin
colostr
antibodi
studi
local
passiv
immun
prevent
dental
cari
review
see
koga
et
al
immun
milk
prepar
cow
immun
mutan
streptococcu
sobrinu
whole
cell
vaccin
inhibit
vitro
glucosyltransferas
fructosyltransferas
enzym
activ
mutan
loimaranta
et
al
promot
aggreg
mutan
inhibit
adher
bacteria
salivaco
hydroxyapatit
particl
loimaranta
et
al
immun
prepar
result
higher
rest
ph
dental
plaqu
adult
volunt
compar
control
group
use
mouth
rins
three
day
loimaranta
et
al
rins
period
immun
product
rel
number
mutan
streptococci
decreas
signifi
cantli
compar
control
chicken
egg
yolk
ig
obtain
immun
hen
mutan
glucan
bind
protein
clear
protect
effect
mutan
infect
cari
develop
rat
model
smith
et
al
mitoma
et
al
immun
cow
fusion
protein
prepar
fusion
salivabind
alaninerich
region
cell
surfac
protein
antigen
pac
glucan
bind
domain
glucosyltransferasei
cell
surfac
protein
mutan
immun
colostrum
prepar
effect
prevent
dental
cari
develop
rat
model
given
concentr
day
day
togeth
cariogen
diet
shimazaki
et
al
examin
effect
immun
colostrum
contain
ig
fusion
protein
adult
subject
antibiot
cetylpyridinium
chlorid
treatment
immun
prepar
inhibit
signifi
cantli
recolon
mutan
saliva
plaqu
compar
control
group
ratio
mutan
total
streptococci
saliva
plaqu
lower
control
group
wei
et
al
studi
combin
effect
specifi
c
colostr
ig
prepar
cari
streptococci
probiot
bacterium
lactobacillu
rhamnosu
gg
atcc
lgg
lgg
ad
milk
earlier
shown
reduc
risk
cari
daycar
children
et
al
lggbacteria
specifi
c
ig
lggferment
milk
synergist
inhibit
adhes
mutan
salivaco
hydroxyapatit
particl
ig
remain
activ
uht
milk
lgg
ferment
milk
whole
period
expect
shelflif
product
thu
rins
bovin
immun
whey
indic
favour
effect
human
dental
plaqu
control
mutan
human
oral
caviti
may
benefi
cial
combin
specifi
c
bovin
milk
antibodi
mutan
streptococci
probiot
lggcontain
milk
product
clostridium
diffi
cile
immun
milk
colon
clostridium
diffi
cile
intestin
may
caus
sever
infecti
diarrhea
coliti
import
virul
factor
toxin
b
associ
develop
diseas
outbreak
c
diffi
cile
infect
often
result
antibiot
treatment
anim
model
bovin
immun
colostrum
prepar
effect
treatment
experiment
c
diffi
cile
diarrhea
van
dissel
et
al
use
prepar
made
milk
cow
immun
c
diffi
cile
toxin
whole
cell
c
diffi
cile
support
treatment
two
week
standard
antibiot
treatment
uncontrol
cohort
studi
nine
patient
histori
relaps
c
diffi
cile
diarrhea
regimen
patient
c
diffi
cile
toxin
disappear
fece
followup
period
month
none
patient
anoth
episod
c
diffi
cile
diarrhea
numan
et
al
assess
effi
caci
c
diffi
cile
immun
milk
prepar
aid
prevent
relaps
c
diffi
cile
patient
immun
milk
administ
oral
gday
divid
three
equal
dose
day
start
two
week
standard
treatment
oral
metronidazol
vancomycin
diseas
episod
follow
relaps
wherea
contemporari
control
relaps
rate
young
et
al
evalu
safeti
immun
milk
administ
c
diffi
cile
patient
similarli
previou
studi
advers
effect
monitor
physic
examin
haematolog
biochem
assess
show
advers
effect
group
mattila
et
al
immun
cow
wholecel
vaccin
made
two
toxigen
c
diffi
cile
strain
immun
whey
prepar
made
colostra
cow
control
doubleblind
random
studi
patient
c
diffi
cile
associ
diarrhea
receiv
oral
g
ig
ml
volum
twice
per
day
week
patient
receiv
mg
metronidazol
twice
per
day
c
diffi
cile
cultur
toxin
test
made
day
respect
day
metronidazol
group
immun
colostrum
group
respect
respond
posit
treatment
author
conclud
immun
colostrum
treatment
somewhat
less
effect
standard
treatment
antibiot
hand
caus
antibiot
resist
problem
alter
normal
colon
bacteri
fl
ora
antibiot
futur
optim
dosag
treatment
time
antigen
use
immun
cow
effi
caci
bovin
milk
ig
prepar
could
improv
treatment
strategi
could
also
use
support
treatment
togeth
convent
antibiot
result
progress
made
membran
separ
chromatograph
techniqu
possibl
isol
ig
bovin
colostrum
chees
whey
larg
scale
progress
facilit
boost
manufactur
ig
concentr
dietari
supplement
ingredi
prepar
market
health
nutrit
function
claim
attach
even
though
clinic
evid
limit
report
scientifi
c
research
therefor
need
fi
eld
substanti
claim
health
benefi
ts
immun
milk
prepar
alreadi
commerci
product
market
quit
well
establish
clinic
evid
effi
caci
main
limit
clinic
use
bovin
milk
antibodi
human
protein
anoth
speci
ig
use
oral
gastrointestin
pathogen
interest
attempt
overcom
limit
transchromosom
calf
clone
produc
human
polyclon
ig
result
fi
sequenti
genet
modifi
cation
seven
consecut
clone
event
calf
report
full
human
igg
total
serum
igg
hyperimmun
calf
anthrax
protect
antigen
full
human
igg
chimer
igg
found
effect
toxinneutr
assay
kuroiwa
et
al
regulatori
statu
regard
product
contain
specifi
c
ig
may
consid
main
reason
product
instanc
contain
specifi
c
ig
cariogen
bacteria
market
countri
regulatori
statu
immun
colostr
prepar
undetermin
long
time
year
product
classifi
ed
pharmaceut
eu
usa
case
diseas
control
also
convent
mean
eg
dental
cari
regulatori
approach
slow
develop
immun
milk
prepar
mani
countri
howev
case
sever
diseas
caus
bacteri
strain
resist
antibiot
c
diffi
cile
regulatori
statu
pharmaceut
delay
hamper
complet
progress
product
develop
hoerr
bostwick
mattila
et
al
current
us
food
drug
administr
fda
accept
safeti
hyperimmun
milk
basi
clinic
studi
show
advers
health
effect
product
gingerich
mcphillip
krissansen
incid
diarrhea
mortal
rate
among
children
mani
area
develop
countri
high
prevent
diarrhea
would
improv
nutrit
statu
health
gener
emerg
antibiot
resist
pathogen
strain
put
emphasi
need
develop
altern
way
prevent
treat
gastrointestin
infect
develop
countri
control
gastrointestin
microbi
fl
ora
becom
integr
part
health
promot
conclud
synergist
effect
ig
probiot
milk
bioactiv
lactoferrin
may
open
new
prospect
develop
novel
mean
prevent
microbi
diseas
nutrit
intervent
